Request Expert

Expert has been a member of the Faculty of a UK university medical school for 21 years. He is Director of the Cellular and Molecular Neuropharmacology Research Group. The group’s principal research interest is 5-HT (5-hydroxytryptamine, serotonin) and has generated an extensive list of published works in international journals including prestigious journals such as Nature, Proceedings of the National Academy of Science USA, Journal of Clinical Investigation, Blood and Gastroenterology. In addition, he is Chairman of the International Union of Basic and Clinical Pharmacology (IUPHAR) Nomenclature Committee for Serotonin Receptors, a member of the Advisory Board of the Medical Research Council (UK), an Expert for France’s INSERM, and is the founder and Chairman of the Cellular Neuropharmacology Special Interest Group within the British Pharmacological Society. He is also Editor-in-Chief and Executive Editor for the international journals Frontiers in Neuropharmacology and Neuropharmacology, respectively.

In addition to his academic-related positions, he is the principle founder and CEO of a venture-capital-backed pharmaceutical research and development company with a therapeutic focus on immune system disorders, based at the Birmingham Research Park. He is also the founder and CSO of a single product virtual company developing a novel therapy for epilepsy that has received approval from the MHRA to perform a Phase II PoC trial in patients. Expert has also generated a number of licensing deals for the Employer giving access to novel reagents developed in his academic laboratory.

Expert has consulted for three of the top five pharmaceutical companies, also a number of pharmaceutical companies in the 'top twenty' as well as SMEs.